Germany - Drugs

Description

The purpose of this notice is to conclude agreements with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book V (SGB V). The invitation to participate is addressed only to pharmaceutical companies or associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act. This is not an open procedure pursuant to Section 15 VgVi. V. m. § 119 para. 3 GWB, but a publication of the invitation to conclude/join rebate contracts with fixed and non-negotiable conditions for all participants, including the amount of the rebate. An unlimited number of pharmaceutical companies or associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act may become contracting parties.
The purpose of this notice is to conclude agreements on the active ingredient "alprostadil (ATC-CODE: C01EA01)" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (discount agreements). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Benazepril (ATC-CODE: C09AA07)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Epoetin zeta (ATC-CODE: B03XA01)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "flunarizine (ATC-CODE: N07CA03)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Infliximab (ATC-CODE: L04AB02)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Levothyroxine (ATC-CODE: H03AA01)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Methylprednisolone (ATC-CODE: H02AB04) Dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Pantoprazole (ATC-CODE: A02BC02) pharmaceutical form: PIJ" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Paricalcitol (ATC-CODE: H05BX02) Dosage form: WKA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Paricalcitol (ATC-CODE: H05BX02) pharmaceutical form: ILO" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Primidone (ATC-CODE: N03AA03) Dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Amifampridine (ATC-CODE: N07XX05)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Chlortalidone (ATC-CODE: C03BA04)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. This announcement serves to conclude agreements on the active ingredient "Fluorouracil - against warts, salicylic acid (ATC-CODE: L01BC52)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. This announcement serves to conclude agreements on the active ingredient "Propranolol (ATC-CODE: C07AA05) Dosage form: LSE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.04.2025. In any case, the contracts will end on 31.05.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Desloratadine - available only on prescription (ATC-CODE: C07AA05) pharmaceutical form: FTA, SMT, TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-04@kbs.de to the CAB.Earliest start of the contract is 01.06.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.05.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The deadline for receipt of accessions is 05.04.2025. In any case, the contracts end on 31.05.2025.

Opportunity closing date

05 April 2025

Value of contract

to be confirmed